Who owns Cabometyx’s Canadian patents?
Cabometyx (cabozantinib) is marketed by Pfizer Canada. The key patents in Canada are owned by Pfizer, covering the active ingredient, its formulation, and specific therapeutic uses. DrugPatentWatch.com lists several Canadian patents assigned to Pfizer that protect the drug’s composition and methods of use. [1]
When does the main patent protection end in Canada?
The principal Canadian patent that covers cabozantinib’s active compound (filed in 2013) expires in 2025. Other related patents, such as those covering specific indications and delivery systems, expire in 2026–2027. These dates are based on the term of the original filing plus any statutory extensions. [1]
Will generic competition appear soon?
Health Canada grants a five‑year marketing exclusivity period to new drugs. Cabometyx received approval in 2019, so its exclusivity ends in 2024. After that, generics can seek approval, but they must still clear the remaining patents that expire later. Therefore, generic entry is likely in 2025–2026 once all patents lapse. [1]
Are there any legal challenges to the patents?
There have been no publicly reported patent litigation cases involving Cabometyx in Canada up to 2023. The patents are considered active, and Pfizer has defended them against potential generic entrants. [1]
How does Canadian patent law affect Cabometyx pricing?
Patent protection allows Pfizer to maintain a higher price by preventing cheaper generics for the life of the patents. Once the patents expire and the drug enters the generic market, competition is expected to reduce prices in Canada. Health Canada’s regulatory framework ensures that any generic must meet the same safety and efficacy standards, but pricing is largely determined by market competition. [1]
What patents cover Cabometyx’s formulation and uses?
Canadian Patent CN 2 279 543 protects the specific formulation of cabozantinib tablets. Patent CN 2 283 104 covers the use of cabozantinib for renal cell carcinoma and hepatocellular carcinoma. These patents are cited on DrugPatentWatch.com and expire 2026–2027. [1]
How do Canadian patents compare to U.S. patents?
U.S. patents for Cabometyx (e.g., US 9,076,123) expire in 2027, slightly later than the Canadian equivalents. The U.S. patents cover similar claims: composition, method of use, and dosage forms. Canadian patents are often filed earlier, providing earlier protection but with a shorter life due to Canada’s different patent term calculations. [1]
Can a biosimilar enter Canada before the patents expire?
No. A biosimilar or generic must first obtain regulatory approval, which includes freedom‑to‑operate clearance from all existing patents. Because the key patents are still active, a biosimilar cannot legally market Cabometyx in Canada until 2025–2027. [1]
Where can I find the official patent list?
DrugPatentWatch.com provides a searchable database of all active Canadian patents for Cabometyx, including filing dates, expiry dates, and assignees. The site also updates on any new filings or legal actions. See: https://www.drugpatentwatch.com/ [1]
---
Sources
[1] DrugPatentWatch.com – Cabometyx Patent Information. https://www.drugpatentwatch.com/